Evaluation of Response by FLT PET in Mesothelioma

Launched by ANKARA UNIVERSITY · May 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method called 18F-FLT PET/CT, which might help doctors evaluate how well chemotherapy is working in patients with pleural mesothelioma, a type of lung cancer often linked to asbestos exposure. The goal is to see if this imaging can provide early insights into how patients are responding to treatment after their first cycle of chemotherapy. By understanding the effectiveness of this method, researchers hope to improve the management of mesothelioma and potentially help patients live longer.

To participate in this trial, patients must have a confirmed diagnosis of pleural mesothelioma and be scheduled to receive platinum-based chemotherapy. They need to be between 65 and 74 years old and provide consent to take part in the study. Participants can expect to undergo a series of imaging tests before and shortly after starting chemotherapy to track their treatment progress. This trial is currently recruiting patients, and it aims to include 25 individuals who meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Having a histopathologically confirmed diagnosis of Pleural Mesolthelioma
• • Patients planned for platinum-based chemotherapy
• • Patients who gave informed consent form to participate in the study
• Exclusion Criteria:
• • Being under 18 years old
• • Patients planned for immunotherapy
• • Patients who did not provide informed consent form to participate in the study